![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Oiginal Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
879kB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
3MB |
| Item Type: | Article |
|---|---|
| Title: | Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study |
| Creators Name: | Augustin, M., Schommers, P., Stecher, M., Dewald, F., Gieselmann, L., Gruell, H., Horn, C., Vanshylla, K., Cristanziano, V.D., Osebold, L., Roventa, M., Riaz, T., Tschernoster, N., Altmueller, J., Rose, L., Salomon, S., Priesner, V., Luers, J.C., Albus, C., Rosenkranz, S., Gathof, B., Fätkenheuer, G., Hallek, M., Klein, F., Suárez, I. and Lehmann, C. |
| Abstract: | BACKGROUND: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients. METHODS: 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model. FINDINGS: We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms. INTERPRETATION: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19. |
| Keywords: | COVID-19, Post-COVID Syndrome, PCS, Long COVID, SARS-CoV-2, Long-Term Health Consequences, Post Infectious Syndrome, Fatigue, Anosmia, Ageusia, Shortness of Breath |
| Source: | The Lancet Regional Health - Europe |
| ISSN: | 2666-7762 |
| Publisher: | Elsevier |
| Volume: | 6 |
| Page Range: | 100122 |
| Date: | July 2021 |
| Official Publication: | https://doi.org/10.1016/j.lanepe.2021.100122 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
